{"title":"抗斑马碱人胞苷脱氨酶突变体对造血干细胞的最佳化学保护","authors":"Hongmei Ruan, M. Black","doi":"10.4172/2157-7412.1000302","DOIUrl":null,"url":null,"abstract":"Acute myeloid leukemia (AML) is the most common type of acute leukemia. According to the National Cancer Institute, the new cases and deaths from AML in the United States in 2016 are estimated to be approximately 19,990 and 13,400, respectively, with a 5 year survival rate of only about 26.6% (http://seer.cancer.gov/statfacts/html/amyl. html). Thus, there is an urgent need to find more effective ways to improve the clinical treatment of AML.","PeriodicalId":89584,"journal":{"name":"Journal of genetic syndromes & gene therapy","volume":"7 1","pages":"1-2"},"PeriodicalIF":0.0000,"publicationDate":"2016-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Zebularine-Resistant Human Cytidine Deaminase Mutants for Optimal Chemoprotection of Hematopoietic Stem Cells\",\"authors\":\"Hongmei Ruan, M. Black\",\"doi\":\"10.4172/2157-7412.1000302\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Acute myeloid leukemia (AML) is the most common type of acute leukemia. According to the National Cancer Institute, the new cases and deaths from AML in the United States in 2016 are estimated to be approximately 19,990 and 13,400, respectively, with a 5 year survival rate of only about 26.6% (http://seer.cancer.gov/statfacts/html/amyl. html). Thus, there is an urgent need to find more effective ways to improve the clinical treatment of AML.\",\"PeriodicalId\":89584,\"journal\":{\"name\":\"Journal of genetic syndromes & gene therapy\",\"volume\":\"7 1\",\"pages\":\"1-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of genetic syndromes & gene therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2157-7412.1000302\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of genetic syndromes & gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2157-7412.1000302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Zebularine-Resistant Human Cytidine Deaminase Mutants for Optimal Chemoprotection of Hematopoietic Stem Cells
Acute myeloid leukemia (AML) is the most common type of acute leukemia. According to the National Cancer Institute, the new cases and deaths from AML in the United States in 2016 are estimated to be approximately 19,990 and 13,400, respectively, with a 5 year survival rate of only about 26.6% (http://seer.cancer.gov/statfacts/html/amyl. html). Thus, there is an urgent need to find more effective ways to improve the clinical treatment of AML.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
